Seeking Alpha
17 Nov 2026, 19:42 UTC · 6h ago
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 Transcript
Impact · against what's priced in
The presentation confirms that Syndax is maintaining growth across its two commercial-stage programs, Revuforj and Niktimvo. While the outlook is positive, the content is primarily descriptive of existing commercial trajectories and known upcoming milestones.
- SNDX+0.10
No priced-in read yet





